Table 4 Proportion of participants with a 40% and 80% reduction in their microfilarial density (MFD) per arm (intention-to-treat analysis)

From: Safety and efficacy of 3- and 5-day regimens of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial

  

Proportion of individuals with MFD reduction >40%

  

PLA

LEV-3

LEV-5

a

b

c

d

D3

No

28 (93.3)

17 (51.5)

16 (57.1)

    
 

Yes

2 (6.7)

16 (48.5)

12 (42.9)

<0.001

<0.001

0.002

0.428

D5

No

27 (90.0)

20 (60.6)

9 (32.1)

    
 

Yes

3 (10.0)

13 (39.4)

19 (67.9)

<0.001

0.014

0.004

0.024

D7

No

22 (91.7)

17 (65.4)

10 (55.6)

    
 

Yes

2 (8.3)

9 (34.6)

8 (44.4)

0.051

0.080

0.040

0.545

D15

No

27 (90.0)

25 (75.8)

20 (71.4)

    
 

Yes

3 (10.0)

8 (24.2)

8 (28.6)

0.372

0.372

0.280

0.462

D30

No

28 (93.3)

26 (78.8)

17 (60.7)

    
 

Yes

2 (6.7)

7 (21.2)

11 (39.3)

0.033

0.196

0.012

0.196

  

Proportion of individuals with MFD reduction >80%

  

PLA

LEV-3

LEV-5

a

b

c

d

D3

No

30 (100.0)

28 (84.8)

27 (96.4)

    
 

Yes

0

5 (15.2)

1 (3.6)

0.136

0.136

0.483

0.280

D5

No

30 (100.0)

30 (90.9)

26 (92.9)

    
 

Yes

0

3 (9.1)

2 (7.1)

0.687

0.548

0.687

0.687

D7

No

24 (100.0)

24 (92.3)

15 (83.3)

    
 

Yes

0 (0.0)

2 (7.7)

3 (16.7)

0.284

0.772

0.284

0.772

D15

No

29 (96.7)

30 (90.9)

27 (96.4)

    
 

Yes

1 (3.3)

3 (9.1)

1 (3.6)

0.988

0.878

0.999

0.678

D30

No

29 (96.7)

32 (97.0)

26 (92.9)

    
 

Yes

1 (3.3)

1 (3.0)

2 (7.1)

0.976

0.999

0.848

0.764

  1. Two-sided Fisher’s exact test with Holm correction for multiple test (adjusted-P values): (a) between the three arms, (b) between LEV-3 and PLA arms, (c) between LEV-5 and PLA arms, and (d) between LEV-5 and LEV-3 arms.
Back to article page